Brisigotti M, Medicina D, Bercich L, Bonetti M F, Fabbretti G, Gambini C, Lo Piccolo M S, Milanaccio C, Rosanda C, Garaventa A, De Bernardi B, Callea F
1o Servizio di Anatomia Patologica, Spedali Civili di Brescia, Italia.
Pediatr Med Chir. 1998 May-Jun;20(3):169-74.
Bone marrow biopsy is very important in diagnosis and follow-up of children affected by neuroblastoma (NB). Between June 1995 and May 1997 we studied 55 patients with NB stage 4. Specimens were obtained at the diagnosis (in 8 patients) and after chemotherapy (in 55 patients) in order to evaluate the effects of treatment on bone marrow disease. 88% of 343 biopsies were representative versus 99% of 639 aspirates. Of 8 stage 4 patients evaluated at diagnosis, 15/16 biopsies versus 9/15 aspirates were positive. Following chemotherapy, out of 298 evaluable sites examined, 111 biopsies versus 30 aspirates (37 versus 10%) were positive. Of 111 positive biopsies 53 showed a focal pattern (35 differentiated, 18 undifferentiated), while 51 showed a diffuse pattern (18 differentiated, 40 undifferentiated). Our results confirm previous literature data indicating a better efficacy of histology versus morphology in detecting residual bone marrow disease (especially in case of focal differentiated pattern). The recent introduction of a specific monoclonal antibody, called anti-GD2, has improved our capacity to detect minimal residual disease in patients' bone marrow. The inclusion of anti-GD2 immunohistochemistry in our evaluation will possibly increase our overall sensitivity to detect minimal residual disease and may provide information capable to direct the physician's decision into a more rational patient's treatment.
骨髓活检在神经母细胞瘤(NB)患儿的诊断及随访中非常重要。1995年6月至1997年5月,我们研究了55例4期NB患者。在诊断时(8例患者)及化疗后(55例患者)获取标本,以评估治疗对骨髓疾病的影响。343次活检中有88%具有代表性,而639次抽吸中有99%具有代表性。在诊断时评估的8例4期患者中,16次活检中有15次呈阳性,而15次抽吸中有9次呈阳性。化疗后,在检查的298个可评估部位中,111次活检呈阳性,而30次抽吸呈阳性(37%对10%)。在111次阳性活检中,53次呈局灶性模式(35次分化型,18次未分化型),而51次呈弥漫性模式(18次分化型,40次未分化型)。我们的结果证实了先前文献数据,表明在检测残留骨髓疾病方面,组织学比形态学具有更好的效果(尤其是局灶性分化型)。最近引入的一种名为抗GD2的特异性单克隆抗体,提高了我们检测患者骨髓中微小残留疾病的能力。在我们的评估中纳入抗GD2免疫组化可能会提高我们检测微小残留疾病的总体敏感性,并可能提供能够指导医生做出更合理的患者治疗决策的信息。